KALARIS THERAPEUTICS, INC. Research and Development Expense
KALARIS THERAPEUTICS, INC. (KLRS) reported Research and Development Expense of $9.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $9.02M, a 6.85% increase year-over-year.
- KALARIS THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $7.57M, a 25.57% increase year-over-year.
- KALARIS THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $7.16M, a 85.90% increase year-over-year.
- KALARIS THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $9.13M, a 74.66% decline year-over-year.
- KALARIS THERAPEUTICS, INC. research and development expense for fiscal 2025 was $30.75M, a 31.72% decline from fiscal 2024.
- KALARIS THERAPEUTICS, INC. research and development expense for fiscal 2024 was $45.04M, a 66.15% decline from fiscal 2023.
- KALARIS THERAPEUTICS, INC. research and development expense for fiscal 2023 was $133.07M, a 11.95% increase from fiscal 2022.
- KALARIS THERAPEUTICS, INC. research and development expense for fiscal 2022 was $118.87M, a 1.54% decline from fiscal 2021.
| Period end | Research and Development Expense 1 month | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.02M 10-Q · filed 2026-08-11 | $16.59M 10-Q · filed 2026-08-11 | $23.75M derived: sum of 3 quarters · filed 2026-08-11 | $32.87M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $7.57M 10-Q · filed 2026-05-12 | $14.73M derived: sum of 2 quarters · filed 2026-05-12 | $23.86M derived: sum of 3 quarters · filed 2026-05-12 | $32.30M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $7.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $16.28M derived: sum of 2 quarters · filed 2026-03-17 | $24.72M derived: sum of 3 quarters · filed 2026-08-11 | $30.75M 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | $9.13M 10-Q · filed 2025-11-12 | $17.57M derived: sum of 2 quarters · filed 2026-08-11 | $23.60M 10-Q · filed 2025-11-12 | $27.45M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $8.44M 10-Q · filed 2026-08-11 | $14.47M 10-Q · filed 2026-08-11 | $18.32M derived: sum of 3 quarters · filed 2026-08-11 | $54.34M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $6.03M 10-Q · filed 2026-05-12 | $9.88M derived: sum of 2 quarters · filed 2026-05-12 | $45.90M derived: sum of 3 quarters · filed 2026-05-12 | $49.11M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $39.87M derived: sum of 2 quarters · filed 2026-03-17 | $43.08M derived: sum of 3 quarters · filed 2026-03-17 | $45.04M 10-K · filed 2026-03-17 | $12.34M 10-K · filed 2025-03-07 | |||
| 2024-09-30 | $36.02M 10-Q · filed 2025-11-12 | $39.23M derived: sum of 2 quarters · filed 2025-11-12 | $41.19M 10-Q · filed 2025-11-12 | $74.56M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-08-31 | $100.00K 10-Q · filed 2025-05-14 | |||||||
| 2024-06-30 | $3.21M 10-Q · filed 2025-08-13 | $93.00K 10-Q · filed 2024-08-09 | $5.17M 10-Q · filed 2025-08-13 | $12.27M 10-Q · filed 2024-08-09 | $38.54M derived: sum of 3 quarters · filed 2025-08-13 | $72.70M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $1.96M 10-Q · filed 2025-05-14 | $12.17M 10-Q · filed 2024-05-13 | $35.33M derived: sum of 2 quarters · filed 2025-05-14 | $69.49M derived: sum of 3 quarters · filed 2025-05-14 | $104.31M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $33.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $67.53M derived: sum of 2 quarters · filed 2025-03-07 | $102.35M derived: sum of 3 quarters · filed 2025-03-07 | $133.07M 10-K · filed 2025-03-07 | ||||
| 2023-09-30 | $34.16M 10-Q · filed 2023-11-02 | $68.98M derived: sum of 2 quarters · filed 2024-08-09 | $99.70M 10-Q · filed 2023-11-02 | $128.12M derived: sum of 4 quarters · filed 2024-08-09 | ||||
| 2023-06-30 | $34.82M 10-Q · filed 2024-08-09 | $65.54M 10-Q · filed 2024-08-09 | $93.96M derived: sum of 3 quarters · filed 2024-08-09 | $123.97M derived: sum of 4 quarters · filed 2024-08-09 | ||||
| 2023-03-31 | $30.72M 10-Q · filed 2024-05-13 | $59.14M derived: sum of 2 quarters · filed 2024-05-13 | $89.14M derived: sum of 3 quarters · filed 2024-05-13 | $120.52M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $28.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $58.42M derived: sum of 2 quarters · filed 2024-03-15 | $89.80M derived: sum of 3 quarters · filed 2024-03-15 | $118.87M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $30.00M 10-Q · filed 2023-11-02 | $61.38M derived: sum of 2 quarters · filed 2023-11-02 | $90.45M 10-Q · filed 2023-11-02 | $132.05M derived: sum of 4 quarters · filed 2023-11-02 | ||||
| 2022-06-30 | $31.38M 10-Q · filed 2023-08-03 | $60.45M 10-Q · filed 2023-08-03 | $102.05M derived: sum of 3 quarters · filed 2023-08-03 | $135.11M derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | $29.07M 10-Q · filed 2023-05-04 | $70.67M derived: sum of 2 quarters · filed 2023-05-04 | $103.73M derived: sum of 3 quarters · filed 2023-05-04 | $129.41M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | $41.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $74.67M derived: sum of 2 quarters · filed 2023-02-15 | $100.34M derived: sum of 3 quarters · filed 2023-02-15 | $120.73M 10-K · filed 2023-02-15 | ||||
| 2021-09-30 | $33.06M 10-Q · filed 2022-11-03 | $58.74M derived: sum of 2 quarters · filed 2022-11-03 | $79.13M 10-Q · filed 2022-11-03 | $95.89M derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | $25.68M 10-Q · filed 2022-08-04 | $46.07M 10-Q · filed 2022-08-04 | $62.83M derived: sum of 3 quarters · filed 2022-08-04 | $80.01M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $20.39M 10-Q · filed 2022-05-05 | $37.15M derived: sum of 2 quarters · filed 2022-05-05 | $54.33M derived: sum of 3 quarters · filed 2022-05-05 | $63.22M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $16.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $33.94M derived: sum of 2 quarters · filed 2022-02-10 | $42.82M derived: sum of 3 quarters · filed 2022-02-10 | $49.66M 10-K · filed 2022-02-10 | ||||
| 2020-09-30 | $17.18M 10-Q · filed 2021-11-05 | $26.07M derived: sum of 2 quarters · filed 2021-11-05 | $32.91M 10-Q · filed 2021-11-05 | $39.59M derived: sum of 4 quarters · filed 2021-11-05 | ||||
| 2020-06-30 | $8.88M 10-Q · filed 2021-08-06 | $15.72M 10-Q · filed 2021-08-06 | $22.41M derived: sum of 3 quarters · filed 2021-08-06 | $28.07M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | $6.84M 10-Q · filed 2021-05-06 | $13.53M derived: sum of 2 quarters · filed 2021-05-06 | $19.18M derived: sum of 3 quarters · filed 2021-05-06 | $21.94M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | $6.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $12.34M derived: sum of 2 quarters · filed 2021-02-12 | $15.10M derived: sum of 3 quarters · filed 2021-02-12 | $16.25M 10-K · filed 2021-02-12 | ||||
| 2019-09-30 | $5.66M 10-Q · filed 2020-11-10 | $8.41M derived: sum of 2 quarters · filed 2020-11-10 | $9.56M 10-Q · filed 2020-11-10 | |||||
| 2019-06-30 | $2.75M 10-Q · filed 2020-09-02 | $3.91M 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |